{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:37:06Z","timestamp":1791941826545,"version":"4.3.4"},"reference-count":94,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cells"],"abstract":"<jats:p>Erectile dysfunction (ED) and cognitive decline share overlapping vascular, metabolic, and neurodegenerative mechanisms, particularly in aging populations. Phosphodiesterase type 5 inhibitors (PDE5-Is), such as sildenafil and vardenafil, are widely used to treat ED by elevating cyclic guanosine monophosphate (cGMP) levels and enhancing vascular function. Emerging evidence suggests that PDE5-Is may also benefit cognitive function by promoting neurovascular coupling, synaptic plasticity, and neuroprotection. This review synthesizes clinical, preclinical, and mechanistic studies on PDE5-Is in the context of learning, memory, and Alzheimer\u2019s disease, highlighting their potential as therapeutic agents for cognitive impairment.<\/jats:p>","DOI":"10.3390\/cells14191505","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:35:49Z","timestamp":1758879349000},"page":"1505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Erectile Dysfunction Drugs as Potential Therapy for Cognitive Decline: Preclinical and Translational Evidence"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-2501","authenticated-orcid":false,"given":"Roberta","family":"Ricciarelli","sequence":"first","affiliation":[{"name":"Section of General Pathology, Department of Experimental Medicine, School of Medical and Pharmacological Sciences, University of Genoa, 16132 Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1743-6109.2010.01778.x","article-title":"Original Articles: Definitions\/Epidemiology\/Risk Factors for Sexual Dysfunction","volume":"7","author":"Lewis","year":"2010","journal-title":"J. Sex. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/jsm.12344","article-title":"Health-Related Characteristics and Unmet Needs of Men with Erectile Dysfunction: A Survey in Five European Countries","volume":"11","author":"Jannini","year":"2014","journal-title":"J. Sex. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/978-3-540-74805-2_16","article-title":"NO\/cGMP-dependent modulation of synaptic transmission","volume":"184","author":"Feil","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fedele, E., and Ricciarelli, R. (2021). Memory Enhancers for Alzheimer\u2019s Dementia: Focus on cGMP. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010061"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00424-013-1373-2","article-title":"New perspectives in cyclic nucleotide-mediated functions in the CNS: The emerging role of cyclic nucleotide-gated (CNG) channels","volume":"466","author":"Podda","year":"2014","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/ijms16011429","article-title":"HCN Channels\u2014Modulators of Cardiac and Neuronal Excitability","volume":"16","author":"Herrmann","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mad.2017.08.001","article-title":"Investigating the amyloid-beta enhancing effect of cGMP in neuro2a cells","volume":"166","author":"Calcagno","year":"2017","journal-title":"Mech. Ageing Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1523\/JNEUROSCI.3607-16.2017","article-title":"Amyloid-\u03b2 Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory","volume":"37","author":"Palmeri","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1042\/BST20130268","article-title":"Cyclic nucleotide phosphodiesterases (PDEs): Coincidence detectors acting to spatially and temporally integrate cyclic nucleotide and non-cyclic nucleotide signals","volume":"42","author":"Maurice","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Brescia, M., and Zaccolo, M. (2016). Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101672"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2174\/138161206778343064","article-title":"Expression, Distribution and Regulation of Phosphodiesterase 5","volume":"12","author":"Lin","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00345-013-1048-9","article-title":"Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide\/cyclic GMP signaling in the human prostate","volume":"31","author":"Waldkirch","year":"2013","journal-title":"World J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0271678X17747177","article-title":"The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review","volume":"38","author":"Pauls","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11010-023-04793-1","article-title":"The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS)","volume":"479","author":"AlRuwaili","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Harms, J.F., Menniti, F.S., and Schmidt, C.J. (2019). Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00837"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110428","DOI":"10.1016\/j.neuropharm.2025.110428","article-title":"A novel selective phosphodiesterase 9 inhibitor, irsenontrine (E2027), enhances GluA1 phosphorylation in neurons and improves learning and memory via cyclic GMP elevation","volume":"273","author":"Ishihara","year":"2025","journal-title":"Neuropharmacology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"110822","DOI":"10.1016\/j.fct.2019.110822","article-title":"Phosphodiesterase inhibitors say NO to Alzheimer\u2019s disease","volume":"134","author":"Nabavi","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2018.06.002","article-title":"Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer\u2019s disease","volume":"138","author":"Gulisano","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Park, M.K., Yang, H.W., Woo, S.Y., Kim, D.Y., Son, D.-S., Choi, B.Y., and Suh, S.W. (2025). Modulation of Second Messenger Signaling in the Brain Through PDE4 and PDE5 Inhibition: Therapeutic Implications for Neurological Disorders. Cells, 14.","DOI":"10.3390\/cells14020086"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3233\/JAD-151104","article-title":"PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease","volume":"52","author":"Teich","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-1119(98)00303-5","article-title":"Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3\u2032,5\u2032-cyclic nucleotide phosphodiesterase","volume":"216","author":"Loughney","year":"1998","journal-title":"Gene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1432-1327.1998.2550391.x","article-title":"Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene","volume":"255","author":"Yanaka","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","article-title":"Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer\u2019s disease human brains","volume":"25","author":"Mengod","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cellsig.2013.10.007","article-title":"Select 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain","volume":"26","author":"Kelly","year":"2014","journal-title":"Cell. Signal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.niox.2009.03.001","article-title":"Neuronal nitric oxide synthase: Structure, subcellular localization, regulation, and clinical implications","volume":"20","author":"Zhou","year":"2009","journal-title":"Nitric Oxide"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0014-5793(93)81210-Q","article-title":"Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle","volume":"316","author":"Nakane","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1161\/01.ATV.19.11.2584","article-title":"Potential Functional Significance of Brain-Type and Muscle-Type Nitric Oxide Synthase I Expressed in Adventitia and Media of Rat Aorta","volume":"19","author":"Schwarz","year":"1999","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tcm.2010.02.007","article-title":"Neuronal Nitric Oxide Synthase and Human Vascular Regulation","volume":"19","author":"Melikian","year":"2009","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ucl.2005.08.007","article-title":"Physiology of Penile Erection and Pathophysiology of Erectile Dysfunction","volume":"32","author":"Dean","year":"2005","journal-title":"Urol. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.2013.799665","article-title":"An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors","volume":"14","author":"Bruzziches","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0091270005276847","article-title":"The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction","volume":"45","author":"Gupta","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jnc.13454","article-title":"Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels","volume":"136","author":"Ugarte","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-beta Load in an Alzheimer\u2019s Disease Mouse Model","volume":"29","author":"Puzzo","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.nlm.2012.02.008","article-title":"Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms","volume":"97","author":"Reneerkens","year":"2012","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"ElHady, A.K., El-Gamil, D.S., Abdel-Halim, M., and Abadi, A.H. (2023). Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091266"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/npp.2014.106","article-title":"Improved Long-Term Memory via Enhancing cGMP-PKG Signaling Requires cAMP-PKA Signaling","volume":"39","author":"Bollen","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","article-title":"Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques","volume":"196","author":"Rutten","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/00008877-199912000-00004","article-title":"Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice","volume":"10","author":"Baratti","year":"1999","journal-title":"Behav. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bbr.2011.02.016","article-title":"Sildenafil, a selective phosphodiesterase type 5 inhibitor, enhances memory reconsolidation of an inhibitory avoidance task in mice","volume":"220","author":"Boccia","year":"2011","journal-title":"Behav. Brain Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","article-title":"Sildenafil restores cognitive function without affecting \u03b2-amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"164","author":"Hervias","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbr.2013.05.017","article-title":"Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP\/PS1 transgenic mice","volume":"250","author":"Zhang","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tins.2018.02.001","article-title":"cAMP, cGMP and Amyloid \u03b2: Three Ideal Partners for Memory Formation","volume":"41","author":"Ricciarelli","year":"2018","journal-title":"Trends Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mad.2015.07.002","article-title":"A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP\/PS1 transgenic mice model","volume":"150","author":"Zhu","year":"2015","journal-title":"Mech. Ageing Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1074\/jbc.M209914200","article-title":"Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis","volume":"278","author":"Andoh","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1484.e15","DOI":"10.1016\/j.neurobiolaging.2011.12.020","article-title":"Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory","volume":"33","author":"Puzzo","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12640-015-9564-6","article-title":"Double-Edged Roles of Nitric Oxide Signaling on APP Processing and Amyloid-\u03b2 Production In Vitro: Preliminary Evidence from Sodium Nitroprusside","volume":"29","author":"Cai","year":"2016","journal-title":"Neurotox. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF02815117","article-title":"Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide","volume":"35","author":"Chalimoniuk","year":"1998","journal-title":"Mol. Chem. Neuropathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/nbdi.2002.0492","article-title":"Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells","volume":"10","author":"Baltrons","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.nbd.2004.07.022","article-title":"Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains","volume":"17","author":"Baltrons","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/nan.12203","article-title":"Decreased levels of guanosine 3\u2032, 5\u2032-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer\u2019s disease","volume":"41","author":"Ugarte","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuropharm.2012.06.052","article-title":"Tadalafil crosses the blood\u2013brain barrier and reverses cognitive dysfunction in a mouse model of AD","volume":"64","author":"Ricobaraza","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2014.10.026","article-title":"Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice","volume":"745","author":"Hasan","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.pbb.2004.09.019","article-title":"Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats","volume":"79","author":"Devan","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.neurobiolaging.2011.03.018","article-title":"Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model","volume":"33","author":"Orejana","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbr.2016.10.046","article-title":"Neuroprotective effects of sildenafil against oxidative stress and memory dysfunction in mice exposed to noise stress","volume":"319","author":"Sikandaner","year":"2017","journal-title":"Behav. Brain Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Liu, S., Li, X., Gao, J., Liu, Y., Shi, J., and Gong, Q. (2018). Icariside II, a Phosphodiesterase-5 Inhibitor, Attenuates Beta-Amyloid-Induced Cognitive Deficits via BDNF\/TrkB\/CREB Signaling. Cell. Physiol. Biochem., 49.","DOI":"10.1159\/000493232"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115058","DOI":"10.1016\/j.expneurol.2024.115058","article-title":"A novel phosphodiesterase 5 inhibitor, RF26, improves memory impairment and ameliorates tau aggregation and neuroinflammation in the P301S tauopathy mouse model of Alzheimer\u2019s disease","volume":"384","author":"Fathalla","year":"2025","journal-title":"Exp. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-022-01034-3","article-title":"Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions","volume":"14","author":"Kang","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Park, Y., Moon, S., Jung, H., Park, S., Kim, J.W., Song, D.-G., In, Y.-H., Han, S.W., Sohn, J.-H., and Lee, C.H. (2025). Mirodenafil improves cognitive function by reducing microglial activation and blood-brain barrier permeability in ApoE4 KI mice. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1579411"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zuccarello, E., Zhang, H., Acquarone, E., Pham, D., Staniszewski, A., Deng, S.-X., Landry, D.W., Arancio, O., and Fiorito, J. (2023). Optimizing metabolic stability of phosphodiesterase 5 inhibitors: Discovery of a potent N-(pyridin-3-ylmethyl)quinoline derivative targeting synaptic plasticity. Bioorg. Med. Chem. Lett., 92.","DOI":"10.1016\/j.bmcl.2023.129409"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/acs.jmedchem.7b00979","article-title":"Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer\u2019s Disease","volume":"60","author":"Fiorito","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1021\/acschemneuro.8b00648","article-title":"Discovery of in Vivo Chemical Probes for Treating Alzheimer\u2019s Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors","volume":"10","author":"Rabal","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/npp.2016.163","article-title":"A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer\u2019s Disease Mice","volume":"42","author":"Rabal","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lee, D.-H., Lee, J.Y., Hong, D.-Y., Lee, E.C., Park, S.-W., Na Jo, Y., Park, Y.J., Cho, J.Y., Cho, Y.J., and Chae, S.H. (2022). ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061348"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.brainresbull.2019.09.001","article-title":"Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer\u2019s disease","volume":"153","author":"Liu","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_69","first-page":"e12412","article-title":"PDE5 inhibitor drugs for use in dementia","volume":"9","author":"Hainsworth","year":"2023","journal-title":"Alzheimer\u2019s Dementia: Transl. Res. Clin. Interv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-pharmtox-040122-034745","article-title":"Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders","volume":"63","author":"Samidurai","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/PL00007092","article-title":"Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: A study with event-related brain potentials","volume":"19","author":"Schultheiss","year":"2001","journal-title":"World J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1023\/A:1017573722074","article-title":"Sildenafil (Viagra): Is there an influence on psychological performance?","volume":"32","author":"Grass","year":"2001","journal-title":"Int. Urol. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3233\/JAD-161006","article-title":"Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer\u2019s Disease","volume":"60","author":"Sheng","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3233\/JAD-190128","article-title":"A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer\u2019s Disease","volume":"70","author":"Samudra","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00213-008-1278-5","article-title":"A placebo-controlled study of sildenafil effects on cognition in schizophrenia","volume":"202","author":"Goff","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-012-2817-7","article-title":"The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans","volume":"225","author":"Reneerkens","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/0269881113477747","article-title":"The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: A behavioral-electroencephalography study","volume":"27","author":"Reneerkens","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ijir.2013.38","article-title":"Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: A double-blind, placebo-controlled study","volume":"26","author":"Shim","year":"2014","journal-title":"Int. J. Impot. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ijir.2011.13","article-title":"Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: A pilot study","volume":"23","author":"Shim","year":"2011","journal-title":"Int. J. Impot. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"432","DOI":"10.9758\/cpn.2019.17.3.432","article-title":"The Effect of Daily Low Dose Tadalafil on Cerebral Perfusion and Cognition in Patients with Erectile Dysfunction and Mild Cognitive Impairment","volume":"17","author":"Choi","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Urios, A., Ordo\u00f1o, F., Garc\u00eda-Garc\u00eda, R., Mangas-Losada, A., Leone, P., Jose Gallego, J., Cabrera-Pastor, A., Megias, J., Fermin Ordono, J., and Felipo, V. (2019). Tadalafil Treatment Improves Inflammation, Cognitive Function, And Mismatch Negativity of Patients with Low Urinary Tract Symptoms and Erectile Dysfunction. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-53136-y"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","article-title":"Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease","volume":"1","author":"Fang","year":"2021","journal-title":"Nat. Aging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e209131","DOI":"10.1212\/WNL.0000000000209131","article-title":"Phosphodiesterase Type 5 Inhibitors in Men with Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study","volume":"102","author":"Adesuyan","year":"2024","journal-title":"Neurology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"fcac247","DOI":"10.1093\/braincomms\/fcac247","article-title":"No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer\u2019s disease and related dementia: Results from the Drug Repurposing for Effective Alzheimer\u2019s Medicines study","volume":"4","author":"Desai","year":"2022","journal-title":"Brain Commun."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Henry, D.S., and Pellegrino, R.G. (2023). A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer\u2019s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0292863"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0094-0143(05)70141-5","article-title":"Oral drug therapy for erectile dysfunction","volume":"28","author":"Giuliano","year":"2001","journal-title":"Urol. Clin. N. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/M21-3445","article-title":"Adverse Events Associated with Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients with Ischemic Heart Disease: A Case-Crossover Study","volume":"175","author":"Holt","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/jch.14435","article-title":"Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications","volume":"24","author":"Kloner","year":"2022","journal-title":"J. Clin. Hypertens."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.mayocp.2012.06.015","article-title":"The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease","volume":"87","author":"Nehra","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Aus\u00f3, E., G\u00f3mez-Vicente, V., and Esquiva, G. (2021). Visual Side Effects Linked to Sildenafil Consumption: An Update. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030291"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0002-9394(02)01338-7","article-title":"A double-blind placebo-controlled evaluation of the acute effects of sildenafil citrate (Viagra) on visual function in subjects with early-stage age-related macular degeneration","volume":"133","author":"Birch","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/WNO.0000000000000186","article-title":"Association Between Phosphodiesterase-5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy","volume":"35","author":"Nathoo","year":"2015","journal-title":"J. Neuroophthalmol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.eururo.2004.10.021","article-title":"Testosterone Regulates PDE5 Expression and in vivo Responsiveness to Tadalafil in Rat Corpus Cavernosum","volume":"47","author":"Zhang","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1172\/JCI70731","article-title":"PDE5 inhibitor efficacy is estrogen dependent in female heart disease","volume":"124","author":"Sasaki","year":"2014","journal-title":"J. Clin. Investig."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/19\/1505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:42:08Z","timestamp":1758879728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/19\/1505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":94,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cells14191505"],"URL":"https:\/\/doi.org\/10.3390\/cells14191505","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}